A5100717741- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Hepatitis B Virus Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Cancer Mechanisms and Therapy
- Ferroptosis and cancer prognosis
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Lipids, and Metabolism
- Cancer-related molecular mechanisms research
- Hepatitis C virus research
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Microtubule and mitosis dynamics
- COVID-19 and healthcare impacts
- Colorectal Cancer Surgical Treatments
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Cytokine Signaling Pathways and Interactions
Shandong First Medical University
2025
Fifth Affiliated Hospital of Sun Yat-sen University
2025
Sun Yat-sen University
2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2015-2024
Huadong Hospital
2024
Fudan University
2024
Guang’anmen Hospital
2023
National Patient Safety Foundation
2022
Weatherford College
2022
National Clinical Research
2021
Liquid biopsies, based on cell free DNA (cfDNA) and proteins, have shown the potential to detect early stage cancers of diverse tissue types. However, most these studies were retrospective, using individuals previously diagnosed with cancer as cases healthy controls. Here, we developed a liquid biopsy assay, named hepatocellular carcinoma screen (HCCscreen), identify HCC from surface antigen hepatitis B virus (HBsAg) positive asymptomatic in community population. The training cohort...
Background & AimsDietary exposure to aflatoxin is an important risk factor for hepatocellular carcinoma (HCC). However, little known about the genomic features and mutations of aflatoxin-associated HCCs compared with not associated exposure. We investigated genetic HCC that can be used differentiate them from this carcinogen.MethodsWe obtained tumor tissues matched non-tumor liver 49 patients, collected 1990 through 2016, at Qidong Liver Cancer Hospital Institute in China—a high-risk region...
// Hong Zhao 1,* , Yuming Guo 2,* Shu Li 2 Ruiqin Han 3 Jianming Ying 4 Hai Zhu Yuanyuan Wang Yin Yuqing Lingzhi Sun Zhaoyi Qingcong Lin Xinyu Bi 1 Yuchen Jiao 5 Hongying Jia Jianjun Zhen Huang Zhiyu Jianguo Zhou Wei Song Kun Meng and Jianqiang Cai Department of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy Medical Sciences Peking Union College, Beijing, P.R. China Beijing Shenogen Biomedical Co., Ltd, National Laboratory Molecular Biology, Institute Basic Sciences,...
Abstract Purpose: This study aimed to investigate the biomarkers of sintilimab (anti–PD-1) plus IBI305 (a bevacizumab biosimilar) in advanced hepatocellular carcinoma (HCC), as well their safety and efficacy. Patients Methods: A total 50 patients with HCC received (200 mg) (7.5 or 15 mg/kg), treated every 3 weeks a phase Ib clinical study. We performed baseline serum cytokine analysis using bead-based multiplex immunoassay immunofluorescence on tissue specimens discover novel response...
Cell-free DNA (cfDNA)–based liquid biopsy is a promising approach for the early detection of cancer. A major hurdle limited yield cfDNA from one blood draw, limiting use most samples to test either mutation or methylation. Here, we develop technology, Mutation Capsule Plus (MCP), which enables multiplex profiling sample, including simultaneous genetic and epigenetic alterations genome-wide discovery methylation markers. With this performed de novo screening markers on 30 hepatocellular...
Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), mostly characterised by HBV integrations, is prevalent worldwide. Previous studies mainly focused on a few hotspot integrations. However, the oncogenic role of other integrations remains unclear. This study aimed to elucidate integration-induced tumourigenesis further.
Postoperative chemotherapy for Colorectal cancer (CRC) patients is not all effective and the main reason might lie in stem cells (CSCs). Emerging studies showed that CSCs overexpress some drug-resistance related proteins, which efficiently transport chemotherapeutics out of cells. Salinomycin, considered as a novel an anticancer drug, found to have ability kill both therapy-resistant To explore potential mechanisms salinomycin could specifically target on colorectal cancers, we firstly...
The role of pyruvate kinase M2 isoform (PKM2) in tumor progression has been controversial. Previous studies showed that PKM2 promoted growth xenograft models; however, depletion the Brca1-loss-driven mammary mouse model accelerates formation. Because oncogenic kinases are frequently activated tumors and phosphorylation promotes growth, we hypothesized by cells confers function, whereas nonphosphorylated is nononcogenic. Indeed, was phosphorylated at tyrosine 105 (Y105) formed dimers...
The receptor-interacting protein kinase 1 (RIPK1) is an essential signaling molecule in pathways for cell survival, apoptosis, and necroptosis. We report here that RIPK1 upregulated human colorectal cancer promotes proliferation when overexpressed a colon line. interacts with mitochondrial Ca2+ uniporter (MCU) to promote by increasing uptake energy metabolism. ubiquitination site of (RIPK1-K377) was critical this interaction MCU function promoting proliferation. These findings identify the...
With poor prognosis and limited treatment options for advanced hepatocellular carcinoma (HCC), development of novel therapeutic agents is urgently needed. This single-arm phase I study sought to assess the safety preliminary efficacy icaritin in human as a potential oral immunotherapy addition immune-checkpoint inhibitors. Eligible HCC patients with Child-Pugh Class A or B were administered fixed dose at either 600 800 mg b.i.d. The primary endpoint was safety, secondary endpoints included...
Abstract Purpose This study aimed to assess efficacy and safety of anlotinib as a first- or second-line treatment for advanced metastatic hepatocellular carcinoma (aHCC) identify the predictive plasma cytokines on anlotinib. Methods It was phase II clinical study. Patients with aHCC were recruited from October 2016 April 2019 divided into two cohorts according previous tyrosine kinase inhibitors (TKIs) therapy. Those without prior TKIs in Cohort 1 2, respectively. All patients took (12...
Background and Aims: We evaluated the efficacy safety of antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 in pretreated advanced biliary tract cancers (BTCs). Approach Results: In this pooled analysis two single‐center, phase Ib clinical trials (TQB2450‐Ib‐05 TQB2450‐Ib‐08 trials), 66 patients with BTCs who had progressed or declined were ineligible for first‐line chemotherapy included. With treatment achieved complete response, 12 partial response...
The prognostic value of the newly raised objective liver function assessment tool, albumin-bilirubin (ALBI) grade, in patients with hepatocellular carcinoma has not been fully validated. We aimed to compare performance ALBI grade specific Child-Pugh (C-P) score predicting prognosis this study.The clinical data 491 C-P class A who underwent resection as initial therapy from January 2000 December 2007 Cancer Hospital, Chinese Academy Medical Sciences (Beijing, China) were retrospectively...
Preventing breast cancer will require the development of targeted strategies that can effectively block disease progression. Tamoxifen and aromatase inhibitors are effective in addressing estrogen receptor-positive (ER(+)) development, but receptor-negative (ER(-)) remains an unmet challenge due to gaps pathobiologic understanding. In this study, we used reverse-phase protein array identify activation Src kinase as early signaling alteration premalignant lesions women who did not respond...
Abstract Background Hepatocellular carcinoma (HCC) is one of the major causes cancer‐related deaths globally. The tumor microenvironment (TME) plays a crucial role in prognosis and treatment HCC. Hence, it important to exploit new biomarkers for survival surveillance TME estimation Methods HCC samples data was collected from Cancer Genome Atlas (TCGA) International Consortium (ICGC) database, clinical were our center. explored with ESTIMATE (Estimation STromal Immune cells MAlignant Tumor...
Abstract Methods accurately predicting the responses of colorectal cancer (CRC) and liver metastasis (CRLM) to personalized chemotherapy remain limited due tumor heterogeneity. This study introduces an innovative patient‐derived CRC CRLM model for preclinical investigation, utilizing 3d‐bioprinting (3DP) technology. Efficient construction homogeneous in vitro 3D models CRC/CRLM is achieved through application primary cells bioprinting with bioink. Genomic histological analyses affirm that...